Korea Q3 Roundup: Record Quarter For Hanmi, Daewoong, Boryung
US Approval For Hanmi’s Rolvedon
Executive Summary
Aside from what was generally a strong quarter for South Korean biopharma firms, Hanmi faces mixed news for its US pipeline, Daewoong’s Fexuclue and Nabota expand their market presence, Boryung builds its oncology business and SK Bioscience unveils an updated growth strategy.
You may also be interested in...
Finance Watch: Genesis, Rapport, Cellares Raise Venture Capital Mega-Rounds
Private Company Edition: Genesis raised $200m, Rapport brought in $150m and Cellares closed a $255m round. Also, Ferring got $300m up front in a royalty deal, Fore Biotherapeutics raised a $75m series D and Vaxxas won a $3.67m Wellcome grant to advance a next-generation typhoid vaccine.
Will The Dark Tunnel For Korean Biopharmas End In 2023?
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.